Leishmaniasis Vaccine

Leishmaniasis vaccines are shots you can get to help protect yourself from getting sick with leishmaniasis. This is a disease spread by sandflies. The vaccine helps your body build its own defense against the parasite that causes the disease. It's not a guarantee you won't get it, but it lowers your chances.

Therapy

What people using Leishmaniasis Vaccine report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Leishmaniasis Vaccine

How It Works

A leishmaniasis vaccine would train the immune system to recognize Leishmania, the single-celled parasite that sand flies pass to people through their bites. Depending on the species, the infection can cause slow-healing skin sores (cutaneous leishmaniasis) or a serious illness of the internal organs called visceral leishmaniasis, or kala-azar. At present, no leishmaniasis vaccine is approved for use in people anywhere. Every human vaccine described here is still a research product. The reason scientists think a vaccine is possible comes from long experience: people who recover from cutaneous leishmaniasis usually resist catching it again. Protection depends mainly on immune cells (T cells) that recognize infected cells, rather than on antibodies alone. That is harder to provoke with a vaccine than the antibody responses most familiar vaccines rely on, and it is a large part of why progress has been slow. Researchers are testing several designs: killed whole parasites, purified parasite proteins combined with an immune-boosting ingredient, a harmless virus engineered to carry parasite genes, and live parasites that have been genetically weakened so they prime the immune system without causing disease. Some candidates are also being studied as therapeutic vaccines, meant to help the body clear an infection that treatment has not fully resolved.

Who It's For

If an effective vaccine is eventually approved, its main users would be people living where leishmaniasis is common, including parts of South Asia, East Africa, the Middle East, the Mediterranean and Latin America, and possibly long-stay travelers, soldiers and field workers. Therapeutic vaccines are being aimed at people with persistent forms of the disease, such as the skin rash that can follow treated kala-azar. For anyone today, the only route to a candidate vaccine is enrollment in a clinical trial. Travelers to areas where the disease occurs protect themselves by avoiding sand fly bites. That means staying in screened or air-conditioned rooms (sand flies are small enough to slip through ordinary screens and nets), sleeping under a fine-mesh bed net treated with insecticide if rooms are not screened, covering skin with long sleeves and pants, and using an insect repellent registered with the US Environmental Protection Agency on exposed skin. There is also no medicine to take in advance to prevent infection.

What It Involves

Taking part in a leishmaniasis vaccine trial looks much like other vaccine research. Volunteers are screened, give informed consent, receive one or more injections, usually into the upper arm muscle, and return for scheduled visits where blood is drawn and any reactions are recorded. Some trials enroll healthy adults in countries without the disease to check safety and immune responses; others take place in affected regions, where participants are followed over time to see whether fewer of them become ill. A newer kind of study, called a controlled human infection model, exposes carefully selected healthy volunteers to a mild skin-infecting strain of the parasite, delivered by laboratory sand flies, under close medical supervision. This lets researchers see early whether a candidate vaccine changes how a skin lesion develops. In therapeutic trials, people who already have the disease receive the vaccine, and their skin or organ symptoms are tracked for weeks to months, with standard treatment offered if they do not improve.

What to Expect

For someone in a trial, the most likely experiences are the usual short-lived vaccine reactions, such as a sore arm, tiredness or a mild fever for a day or two, along with the time commitment of repeated follow-up visits. Participants are not told to rely on the vaccine for protection, because its effect is exactly what the study is trying to find out, and some participants receive a placebo. For the public, the realistic expectation is a long road. Several candidates have been safe and have produced measurable immune responses, but a measurable response in the blood has not yet translated into proven protection. Any future approval would also depend on which form of the disease and which parasite species a vaccine covers, since protection against one may not extend to another.

What the Evidence Says

The largest body of evidence comes from vaccines made of killed whole parasites. These are the only candidates that have reached large late-stage field trials, in both the Middle East and the Americas. They proved safe, but none showed reliable protection against the disease. Purified-protein vaccines produced immune responses in early human trials and did not cause serious safety problems, but none has advanced to approval. A vaccine built on a chimpanzee adenovirus (a cold virus altered so it cannot multiply) called ChAd63-KH produced strong T-cell responses in healthy volunteers. When it was tested as a treatment for persistent post-kala-azar skin disease in Sudan, a placebo-controlled trial found no meaningful difference: about 15% of vaccinated participants and 11% of placebo recipients had near-complete clearing at three months. The strongest evidence that immunity can be induced on purpose comes from leishmanization, a historical practice in Israel, Iran and the former Soviet Union in which live parasites were deliberately introduced into the skin. It reduced later natural infections, but it worked by causing a real sore, which is why it was abandoned. Genetically weakened parasites designed to give similar immunity without the sore have protected laboratory animals, and at least one strain has been prepared for human testing. Vaccines for dogs, which can carry the parasite, have reduced disease in vaccinated dogs in field trials, but those results do not show that a vaccine would protect people.

Risks & Considerations

Because there is no approved product, the main consideration is not a side effect but a false sense of security. No vaccine or preventive medicine exists for travelers, so bite prevention remains essential, and anyone who develops a sore that does not heal or an unexplained prolonged fever after time in an affected area should tell a clinician about the trip. Visceral leishmaniasis is treatable but is usually fatal without treatment, so that history matters. Within trials, the vaccines tested so far have mostly caused mild, temporary reactions, and the ChAd63-KH trial reported no serious adverse events. Live weakened-parasite vaccines carry a theoretical risk that the parasite could regain its ability to cause disease, which is one reason developers are building in more than one genetic change and moving cautiously. Controlled infection studies involve a deliberate skin infection that needs monitoring and sometimes treatment, so they enroll only healthy, fully informed adults. A vaccine given to a pet dog is a veterinary decision about the dog's health. It does not protect the people in the household.

Questions to Ask Your Doctor

  1. 1.Is there any vaccine or medicine I can take before traveling to an area where leishmaniasis occurs, or does protection depend entirely on avoiding sand fly bites?
  2. 2.Which form of leishmaniasis is common where I am going, and what symptoms should prompt me to get checked after I return?
  3. 3.Are there leishmaniasis vaccine trials I might be eligible for, and what would participation involve?
  4. 4.If I have a persistent form of leishmaniasis, would a therapeutic vaccine trial make sense alongside standard treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.